Valuation: Abpro Corporation

Market Cap 22.99L 20.49L 18.97L 17.17L 32.34L 22Cr 32.73L 2.27Cr 89.25L 11Cr 86.26L 84.46L 36Cr P/E 2024
-2.41x
P/E 2025 -3.27x
Enterprise Value 23.79L 21.2L 19.63L 17.77L 33.47L 22Cr 33.87L 2.35Cr 92.35L 12Cr 89.26L 87.4L 38Cr EV / Sales 2024
497x
EV / Sales 2025 -
Free-Float
83.91%
Yield 2024 *
-
Yield 2025 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 22.99L
-0.21%-6.36%+49.00%+74.13% 6.63TCr
-0.22%+6.53%+11.68%+90.35% 5.29TCr
+0.82%+5.41%+8.05%+74.45% 5.48TCr
+2.12%+4.80%+25.57%+49.46% 4.41TCr
+0.62%+9.97%+22.42%+129.08% 4.37TCr
+0.51%+1.28%+266.42%+967.83% 4.21TCr
+0.10%+9.96%+17.15%+59.33% 3.4TCr
-1.30%-3.61%+37.37%+7.16% 2.62TCr
+0.69%+5.60%+36.60%+26.39% 2.34TCr
Average +0.28%+4.78%+52.70%+164.24% 4.31TCr
Weighted average by Cap. +0.33%+4.67%+51.76%+168.25%

Financials

2024 2025
Net sales 2L 2L 2L 1L 3L 1.73Cr 3L 18.1L 7L 90.77L 7L 7L 2.89Cr -
Net income -72.32L -64.44L -59.66L -53.99L -1.02Cr -68Cr -1.03Cr -7.15Cr -2.81Cr -36Cr -2.71Cr -2.66Cr -114.31Cr -28.92L -25.77L -23.86L -21.59L -40.68L -27Cr -41.16L -2.86Cr -1.12Cr -14Cr -1.08Cr -1.06Cr -46Cr
Net Debt 5L 4L 4L 4L 7L 4.51Cr 7L 47.28L 18.55L 2.37Cr 17.93L 17.56L 7.56Cr 80T 71.29T 66T 59.73T 1L 75.49L 1L 8L 3L 39.68L 3L 3L 1.26Cr
Logo Abpro Corporation
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Employees
-